MRI/TRUS FUSION guided biopsy as first approach in ambulatory setting: Feasibility and performance of a new fusion device

  • Daniele D'Agostino | dott.dagostino@gmail.com Department of Robotic Urological Surgery, Abano Terme Hospital, Abano Terme, Italy.
  • Federico Mineo Bianchi Department of Urology, University of Bologna, Bologna, Italy.
  • Daniele Romagnoli Department of Robotic Urological Surgery, Abano Terme Hospital, Abano Terme, Italy.
  • Marco Giampaoli Department of Robotic Urological Surgery, Abano Terme Hospital, Abano Terme, Italy.
  • Paolo Corsi Department of Robotic Urological Surgery, Abano Terme Hospital, Abano Terme, Italy.
  • Alessandro Del Rosso Department of Robotic Urological Surgery, Abano Terme Hospital, Abano Terme, Italy.
  • Riccardo Schiavina Department of Urology, University of Bologna, Bologna, Italy.
  • Eugenio Brunocilla Department of Urology, University of Bologna, Bologna, Italy.
  • Angelo Porreca Department of Robotic Urological Surgery, Abano Terme Hospital, Abano Terme, Italy.

Abstract

Purpose: To evaluate the detection rate of Magnetic Resonance Imaging/Transrectal Ultrasound (MRI/TRUS) Fusion Biopsy performed in a series of patients with suspicious prostate cancer in an ambulatory setting.
Materials and methods: Between March 2018 and January 2019 a series of 155 patients undergoing MRI/TRUS fusionguided biopsy were prospectively enrolled. All patients presented a suspected diagnosis for prostate cancer because of raised Prostate Specific Antigen (PSA) serum level and/or abnormal physical examination (digital rectal examination), and showed at least one suspicious area at the multiparametric Magnetic Resonance Imaging (mpMRI).
Results: Of 155 patients, 58 (37.4%) were biopsy-naïve, 97 (62.6%) had at least 1 previous negative TRUS-guided biopsy. The median age of the patient cohort was 66 years (IQR, 61- 69); the median prebiopsy PSA value was 7.1 ng/ml (IQR, 5- 8.9). Overall, the Fusion-TB findings were positive in 94 of 155 patients with a detection rate (DR) of 60%; a significantly high DR was obtained in terms of clinically significant prostate cancer (csPCa) by Fusion-TB (61 pts; 41.9%). The overall DR in the 121 biopsy-naive patients was 60.6%. In the subgroup of the 34 patients with at least 1 previous set of TRUS-GB, overall DR was 39.3% (35/50).
Conclusions: The targeted MRI/TRUS fusion-guided biopsy represents a safe and accurate approach for diagnosis of csPCa, especially in patient with previous TRUS guided biopsy negative and suspicious prostate cancer.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Author Biography

Daniele D'Agostino, Department of Robotic Urological Surgery, Abano Terme Hospital, Abano Terme

urology

Published
2020-01-13
Info
Issue
Section
Original Papers - Prostate
Keywords:
Prostate cancer, Magnetic Resonance, Prostate biopsy
Statistics
  • Abstract views: 591

  • PDF: 243
How to Cite
D’Agostino, D., Mineo Bianchi, F., Romagnoli, D., Giampaoli, M., Corsi, P., Del Rosso, A., Schiavina, R., Brunocilla, E., & Porreca, A. (2020). MRI/TRUS FUSION guided biopsy as first approach in ambulatory setting: Feasibility and performance of a new fusion device. Archivio Italiano Di Urologia E Andrologia, 91(4), 211-217. https://doi.org/10.4081/aiua.2019.4.211

Most read articles by the same author(s)